SLC7A5 and cancer: Inhibitors of LAT1 are extensively developed for the treatment of malignant tumors and JPH203, the most potent small compound inhibitor of LAT1, is in clinical trials for solid tumors such as colorectal cancer and biliary tract cancer20.